['cancer of stomach']
['nab-paclitaxel', 'folfox']

        Inclusion Criteria:

          -  Signed and dated informed consent, and willing and able to comply with protocol
             requirements,

          -  Histologically or cytologically proven adenocarcinoma of the low oesophagus or of the
             stomach, (from 1/3 inferior of the oesophagus to pylorus)

          -  HER2 negative tumors

          -  Localized and operable disease confirmed (stage I-III),

          -  No prior therapy for localized disease ,

          -  Age ≥18 years,

          -  Performance status (PS) 0-2,

          -  Haematological status: neutrophils (ANC) > 2.0x109/L; platelets >100x109/L;
             haemoglobin ≥9g/dL,

          -  Adequate renal function: serum creatinine level <150µM and creatinine clearance test >
             30mL/min,

          -  Adequate liver function: AST (SGOT) and ALT (SGPT) ≤2.5xULN (Upper Limit of Normal)

          -  Total bilirubin ≤1.5 x ULN,

          -  Albumin ≥25g/L

          -  Baseline evaluations performed before inclusion: clinical and blood evaluations no
             more than 2 weeks (14 days) prior to inclusion, tumor assessment (CT-scan, evaluation
             of non-measurable lesions) no more than 3 weeks (21 days) prior to inclusion,

          -  Female patients must be surgically sterile, or be postmenopausal, or must commit to
             using reliable and appropriate methods of contraception during the study and during at
             least six months after the end of study treatment (when applicable). All female
             patients with reproductive potential must have a negative pregnancy test (β HCG)
             within 72 hours days prior to starting nab-paclitaxel neo-adjuvant and adjuvant
             treatment. Breastfeeding is not allowed. Male patients must agree to use effective
             contraception in addition to having their partner use a contraceptive method as well
             during the trial and during at least six months after the end of the study treatment,

          -  Registration in a national health care system (CMU included for France).

        Exclusion Criteria:

          -  Metastatic disease (stage IV)

          -  Non operable primary tumor

          -  Patient using warfarin,

          -  Uncontrolled hypercalcemia (corrected serum calcium > 2.55 mmol/l),

          -  Pre-existing permanent neuropathy (NCI grade ≥2),

          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency,

          -  Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted
             therapy, immunotherapy),

          -  Treatment with any other investigational medicinal product within 28 days prior to
             study entry,

          -  Other serious and uncontrolled non-malignant disease (eg. active infection requiring
             systemic therapy, coronary stenting or myocardial infarction or stroke in the past 6
             months),

          -  Known or historical active infection with HIV, or known active infection untreated
             with hepatitis B or hepatitis C.

          -  Other concomitant or previous malignancy, except: i/ adequately treated in-situ
             carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin,
             iii/ cancer in complete remission for >5 years,

          -  Patients with known allergy to any excipient of study drugs,

          -  Concomitant administration of live, attenuated virus vaccine such as yellow fever
             vaccine and concomitant administration of prophylactic phenytoin

          -  Patient with any medical or psychological condition, deemed by the investigator to
             likely interfere with patient's ability to sign informed consent or cooperate and
             participate in the study, including tutelage or guardianship.
      